This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1999;12(2):131-5.

doi: 10.1006/pupt.1999.0181.

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

T J Torphy¹, M S Barnette, D C Underwood, D E Griswold, S B Christensen, R D Murdoch, R B Nieman, C H Compton

Affiliations

PMID: 10373396
DOI: 10.1006/pupt.1999.0181

Review

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

T J Torphy et al. Pulm Pharmacol Ther. 1999.

. 1999;12(2):131-5.

doi: 10.1006/pupt.1999.0181.

Authors

T J Torphy¹, M S Barnette, D C Underwood, D E Griswold, S B Christensen, R D Murdoch, R B Nieman, C H Compton

Affiliation

¹ Division of Cardiovascular and Pulmonary Research, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, 19406, USA.

PMID: 10373396
DOI: 10.1006/pupt.1999.0181

No abstract available

PubMed Disclaimer

Similar articles

An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Giembycz MA. Giembycz MA. Br J Clin Pharmacol. 2006 Aug;62(2):138-52. doi: 10.1111/j.1365-2125.2006.02640.x. Br J Clin Pharmacol. 2006. PMID: 16842388 Free PMC article. Review.
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. Gamble E, et al. Am J Respir Crit Care Med. 2003 Oct 15;168(8):976-82. doi: 10.1164/rccm.200212-1490OC. Epub 2003 Jun 19. Am J Respir Crit Care Med. 2003. PMID: 12816740 Clinical Trial.
The potential of PDE4 inhibitors in asthma or COPD.
Spina D. Spina D. Curr Opin Investig Drugs. 2000 Oct;1(2):204-13. Curr Opin Investig Drugs. 2000. PMID: 11249575 Review.
PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.
Diamant Z, Spina D. Diamant Z, et al. Pulm Pharmacol Ther. 2011 Aug;24(4):353-60. doi: 10.1016/j.pupt.2010.12.011. Epub 2011 Jan 19. Pulm Pharmacol Ther. 2011. PMID: 21255672 Review.
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ. Griswold DE, et al. J Pharmacol Exp Ther. 1998 Nov;287(2):705-11. J Pharmacol Exp Ther. 1998. PMID: 9808700

See all similar articles

Cited by

Clinical pharmacology of Cilomilast.
Down G, Siederer S, Lim S, Daley-Yates P. Down G, et al. Clin Pharmacokinet. 2006;45(3):217-33. doi: 10.2165/00003088-200645030-00001. Clin Pharmacokinet. 2006. PMID: 16509757 Review.
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.
Currie GP, Butler CA, Anderson WJ, Skinner C. Currie GP, et al. Br J Clin Pharmacol. 2008 Jun;65(6):803-10. doi: 10.1111/j.1365-2125.2008.03155.x. Epub 2008 Mar 13. Br J Clin Pharmacol. 2008. PMID: 18341675 Free PMC article. Review.
Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.
Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberté F, Liu S, Huang Z, Conti M, Chan CC. Robichaud A, et al. J Clin Invest. 2002 Oct;110(7):1045-52. doi: 10.1172/JCI15506. J Clin Invest. 2002. PMID: 12370283 Free PMC article.
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Giembycz MA, Field SK. Giembycz MA, et al. Drug Des Devel Ther. 2010 Jul 21;4:147-58. doi: 10.2147/dddt.s7667. Drug Des Devel Ther. 2010. PMID: 20689641 Free PMC article. Review.
Targeting Metalloenzymes for Therapeutic Intervention.
Chen AY, Adamek RN, Dick BL, Credille CV, Morrison CN, Cohen SM. Chen AY, et al. Chem Rev. 2019 Jan 23;119(2):1323-1455. doi: 10.1021/acs.chemrev.8b00201. Epub 2018 Sep 7. Chem Rev. 2019. PMID: 30192523 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information